Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TOPMed BCC-PREG Burwick-BIDMC (Boston-Colombia Collaborative Adverse Pregnant Outcome Study)

ABSTRACT: TOPMed BCC-PREG Burwick-BIDMC (Boston-Colombia Collaborative Adverse Pregnant Outcome Study)

PROVIDER: PRJNA989357 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

NHLBI TOPMed: Boston-Brazil Collaborative Project for Whole Genome Sequencing of Sickle Cell Disease Patients

Project description:NHLBI TOPMed: Boston-Brazil Collaborative Project for Whole Genome Sequencing of Sickle Cell Disease Patients

| PRJNA472118 | ENA

NHLBI TOPMed: Boston-Brazil Collaborative Project for Whole Genome Sequencing of Sickle Cell Disease Patients

Project description:NHLBI TOPMed: Boston-Brazil Collaborative Project for Whole Genome Sequencing of Sickle Cell Disease Patients

| PRJNA472119 | ENA

Metarhizium sp. BCC 4849 isolate:BCC 4849

Project description:Metarhizium sp. BCC 4849 isolate:BCC 4849 Genome sequencing and assembly

| PRJNA1078065 | ENA

Expression data from mouse basal cell carcinoma (BCC) and normal epidermis, and BCC cell line treated with cyclopamine

Project description:Activation of the Sonic hedgehog (Shh) signaling pathway due to Patched 1 (PTCH1) mutation is a key event in sporadic and familial basal cell carcinoma (BCC) development. To find out the specific pathway for therapeutic intervention, we developed a mouse BCC model by skin specific Ptch1 inactivation, and sought to identify novel Shh targets. We used microarrays to identify up-regulated genes in mouse BCC. We used microarrays to identify down-regulated genes in mouse BCC cell line by cyclopamine.

2018-01-15 | GSE20065 | GEO

Murine BCC Cells: dio3 interfered vs control

Project description:MicroRNA expression profiling of mouse basal cell carcinoma (BCC) cells comparing BCC cells transfected with a stealth for dio3 transcript or control stealth-RNA. Two-condition experiment, Stealth-D3 vs Stealth-CTR cells. Biological replicates: 3 Stealth-D3 and 3 Stealth-CTR, independently grown and harvested. Single RNA were pooled. One replicate per array.

2016-02-24 | E-GEOD-78265 | biostudies-arrayexpress

Murine BCC Cells: dio3 interfered vs control

Project description:MicroRNA expression profiling of mouse basal cell carcinoma (BCC) cells comparing BCC cells transfected with a stealth for dio3 transcript or control stealth-RNA.

2016-02-24 | GSE78265 | GEO

CIDR Preterm Birth Boston Cohort

Project description:CIDR Preterm Birth Boston Cohort

| PRJNA75541 | ENA

Boston Early-Onset COPD Study

Project description:Boston Early-Onset COPD Study

| PRJNA326857 | ENA

Identification of anaplastic lymphoma kinase as a candidate of new therapeutic target for BCC

Project description:Background; Basal cell carcinoma (BCC) is the most common cancer in humans. The pathogenesis of BCC is associated with the sonic hedgehog (SHH) signaling pathway. Vismodegib, a smoothened inhibitor, that targets this pathway is now in clinical use for advanced BCC patients, but its efficacy is limited. Therefore, new therapeutic options for this cancer are required. Methods; We studied gene expression profiling of BCC tumour tissue coupled with laser capture microdissection to identify tumor specific receptor tyrosine kinase expression that can be targeted by small molecule inhibitors. The expression of selected molecules was confirmed by quantitative RT-PCR (qRT-PCR) and by immunohistochemistry. The action of kinase inhibitors was examined on primary normal human epidermal keratinocytes. Results; We found a >250 fold change increase (false discovery rate <10-4) of the oncogene, anaplastic lymphoma kinase (ALK) as well as its ligands, pleiotrophin and midkine in BCC compared to microdissected normal epidermis. qRT-PCR confirmed increased expression of ALK (p<0.05). Stronger staining of phosphorylated ALK in BCC tumour nests than normal skin was observed by immunohistochemistry. Additionally, Crizotinib, an FDA-approved ALK inhibitor, reduced keratinocyte proliferation in culture, whereas a c-Met, another receptor tyrosine kinase, inhibitor did not. Crizotinib significantly reduced the expression of GLI1 and CCND2 mRNA by approximately 60% and 20%, respectively (p<0.05). Conclusions; Our data suggest that ALK may increase GLI1 expression in parallel with the conventional SHH-pathway and promotes keratinocyte proliferation. Furthermore, an ALK inhibitor alone or in combination with targeting SHH-pathway molecules may be a potential treatment for BCC patients. Laser capture microdissection was performed on 5 cases of nodular/superficial BCC, 5 cases of infiltrative BCC.

2013-01-30 | E-GEOD-42109 | biostudies-arrayexpress

Xylaria sp. BCC 1067

Project description:Genome sequence of Xylaria sp. BCC 1067

| PRJNA531792 | ENA